346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Bibliographic Details
Main Authors: Christian Poehlein, Joseph Burgents, Christian Gratzke, Cuizhen Niu
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-645950c7d2184b2da3cce1c1caccdf32
record_format Article
spelling doaj-645950c7d2184b2da3cce1c1caccdf322020-12-11T10:01:34ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0346346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)Christian Poehlein0Joseph Burgents1Christian Gratzke2Cuizhen Niu3Aff400 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA 2Merck and Co., Inc., Kenilworth, NJ, USA1University Medical Center Freiburg, Freiburg, Germany2MSD China, Beijing, China
collection DOAJ
language English
format Article
sources DOAJ
author Christian Poehlein
Joseph Burgents
Christian Gratzke
Cuizhen Niu
spellingShingle Christian Poehlein
Joseph Burgents
Christian Gratzke
Cuizhen Niu
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Journal for ImmunoTherapy of Cancer
author_facet Christian Poehlein
Joseph Burgents
Christian Gratzke
Cuizhen Niu
author_sort Christian Poehlein
title 346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
title_short 346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
title_full 346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
title_fullStr 346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
title_full_unstemmed 346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
title_sort 346 keynote-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (adt) for patients with metastatic hormone-sensitive prostate cancer (mhspc)
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT christianpoehlein 346keynote991phase3studyofpembrolizumabplusenzalutamideandandrogendeprivationtherapyadtforpatientswithmetastatichormonesensitiveprostatecancermhspc
AT josephburgents 346keynote991phase3studyofpembrolizumabplusenzalutamideandandrogendeprivationtherapyadtforpatientswithmetastatichormonesensitiveprostatecancermhspc
AT christiangratzke 346keynote991phase3studyofpembrolizumabplusenzalutamideandandrogendeprivationtherapyadtforpatientswithmetastatichormonesensitiveprostatecancermhspc
AT cuizhenniu 346keynote991phase3studyofpembrolizumabplusenzalutamideandandrogendeprivationtherapyadtforpatientswithmetastatichormonesensitiveprostatecancermhspc
_version_ 1724386567016939520

Similar Items